Edition:
India

Nanobiotix SA (NANOB.PA)

NANOB.PA on Paris Stock Exchange

13.89EUR
9:11pm IST
Change (% chg)

€-0.24 (-1.70%)
Prev Close
€14.13
Open
€14.13
Day's High
€14.13
Day's Low
€13.80
Volume
33,993
Avg. Vol
103,391
52-wk High
€22.50
52-wk Low
€11.25

Chart for

About

Nanobiotix SA is a France-based oncology focused nanomedicine company. It is engaged in developing nanoparticle technology. It develops new tools for cancer which utilize a physical mode of action at the cellular level of the cancer cell. This disruptive approach may reshape future treatment opportunities. The Company's NanoXray... (more)

Overall

Beta: 1.61
Market Cap(Mil.): €301.54
Shares Outstanding(Mil.): 17.56
Dividend: --
Yield (%): --

Financials

BRIEF-Nanobiotix Presents Data From Phase I/II Liver Cancers Trial Of NBTXR3

* NANOBIOTIX PRESENTS FIRST PROMISING DATA FROM PHASE I/II LIVER CANCERS TRIAL OF NBTXR3 AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY GASTROINTESTINAL ANNUAL MEETING

22 Jan 2018

BRIEF-Nanobiotix Partners With The Providence Cancer Institute To Run Immunotherapeutic Preclinical Research In Pancreatic Cancers

* NANOBIOTIX PARTNERS WITH THE PROVIDENCE CANCER INSTITUTE TO RUN IMMUNOTHERAPEUTIC PRECLINICAL RESEARCH IN PANCREATIC CANCERS

11 Jan 2018

BRIEF-Nanobiotix: FDA Approves First Immuno-Oncology Trial

* NANOBIOTIX : FDA APPROVES NANOBIOTIX'S FIRST IMMUNO-ONCOLOGY TRIAL

26 Dec 2017

BRIEF-Nanobiotix Q3 revenue down at 33.0‍​ million euros

* Q3 REVENUE EUR 33.0‍​ MILLION VERSUS EUR 58.6 MILLION YEAR AGO Source text: http://bit.ly/2zKWYHz Further company coverage: (Gdynia Newsroom)

15 Nov 2017

BRIEF-Nanobiotix completes new share issue for about 27.2 million euros

* NANOBIOTIX SUCCESSFULLY COMPLETES APPROXIMATELY EUR 27.2 MILLION PLACEMENT OF NEW SHARES

31 Oct 2017

BRIEF-Nanobiotix completes patient inclusion for phase II/III trial of NBTXR3

* NANOBIOTIX COMPLETES PATIENT INCLUSION FOR PHASE II/III TRIAL OF NBTXR3 IN SOFT TISSUE SARCOMA

23 Oct 2017

BRIEF-Nanobiotix to conduct its first clinical trial with NBTXR3 in the U.S.‍​

* PLANS TO CONDUCT ITS FIRST CLINICAL TRIAL WITH NBTXR3 IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS IN U.S.‍​

28 Sep 2017

BRIEF-Nanobiotix H1 net loss widens to 12.2 million euros

* H1 NET LOSS EUR 12.2 MILLION VERSUS LOSS OF EUR 10.2 MILLION YEAR AGO

31 Aug 2017

Earnings vs. Estimates